The U.S. daily death average from COVID-19 is steadily rising, with an average of 1,550 new fatalities each day -- up by about 44% since Christmas, according to federal data.

This average is still significantly lower than last winter when the nation peaked at about 3,400 deaths per day.

Indiana now has the nation's highest death rate, followed by Delaware and Wyoming.

Nearly 146,000 Americans with COVID-19 are currently in hospitals -- a pandemic high -- according to new data from the Department of Health and Human Services.

On average, more than 18,500 virus-positive Americans are being admitted to the hospital each day, a figure which has more than doubled over the last month. It's still not clear how many COVID-19-positive people in hospitals were admitted to the hospital for the virus or admitted for other reasons and coincidentally tested positive.

About 30% of hospitals (with available data) are facing critical staffing shortages.

-ABC News' Arielle Mitropoulos

With 48,686 New Yorkers testing positive on Monday, the state saw a case drop for the first time in weeks, Gov. Kathy Hochul announced.

Hochul called this "a glimmer of hope," but warned, "we are not at the end."

While hospitalizations continue to rise, "the rate of increase is slowing, and to us that is very encouraging," the governor said.

-ABC News' Will Gretsky

Chicago residents can head to their local alderman's office to get a free KN95 mask as the city distributes 1.5 million of them on Tuesday, ABC Chicago station WLS reported.

With another 4,793 daily cases, Chicago's test positivity rate stands at 18.9% as of Tuesday, according to city data.

The U.S. government is buying 600,000 more doses of sotrovimab, the only the monoclonal antibody treatment expected to hold up against omicron, according to the drug makers, GlaxoSmithKline and Vir Biotechnology.

These doses are set to be delivered to the government over the next two months, the drug makers said.

This brings total sotrovimab doses purchased by the federal government to approximately 1 million. 

Short supply of sotrovimab has been a growing concern for the White House as omicron spreads.

Until recently the government had not invested in buying bulk stock of sotrovimab, as it has with other monoclonal treatments. The government spent billions buying Regeneron and Eli Lilly's products to ensure there would be enough supply, but both of those may not hold up against omicron.

-ABC News' Sasha Pezenik